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Symptoms of depression and anxiety appeared in mice after they had been subjected to a combination of forced swimming for
15min followed by being kept in cages that were sequentially subjected to leaning, drenching, and rotation within 1-2 days for a
total of 3 weeks. The animals were then evaluated by the tail-suspension test, elevated plus-maze test, and open-ﬁeld test at 1 day
after the end of stress exposure. Using these experimental systems, we found that 10-hydroxy-trans-2-decenoic acid (HDEA), an
unsaturated fatty acid unique to royal jelly (RJ), protected against the depression and anxiety when intraperitoneally administered
once a day for 3 weeks simultaneously with the stress loading. Intraperitoneally administered RJ, a rich source of HDEA, was also
protective against the depression, but RJ given by the oral route was less eﬀective. Our present results demonstrate that HDEA and
RJ, a natural source of it, were eﬀective in ameliorating the stress-inducible symptoms of depression and anxiety.
1.Introduction
Royal jelly (RJ), which is fed to the queen honeybee, has a
variety of biological activities towards various types of cells.
For instance, RJ exhibits immunomodulatory properties [1–
3] and inhibits the development of atopic dermatitis-like
skin lesions [4]. Earlier we found that RJ has the ability
t oi n d u c en e u r i t e sf r o mc u l t u r e dr a tp h e o c h r o m o c y t o m a
PC12 cells and identiﬁed an adenosine monophosphate
(AMP) analog, AMP N1- o x i d e ,a sa na c t i v ee n t i t y[ 5].
As AMP N1-oxide is a unique compound of RJ, the
eﬀects of RJ on the nervous system may be attributed
to this compound. Further, RJ contains another unique
component, 10-hydroxy-trans-2-decenoic acid (HDEA), an
unsaturated fatty acid [6]. HDEA has been reported to
have many pharmacological activities such as antitumor
activity [7], collagen production-promoting activity [8],
and antibiotic activity [9]. We recently found that HDEA
increases neurogenesis, but decreases glial generation, of
cultured neural stem/progenitor cells (NSCs) [10]a sw e l l
as the production of neurotrophins including brain-derived
neurotrophic factor (BDNF) [11]. These results prompted us
totestthetherapeuticeﬀectofHDEAondepression,because
signiﬁcant neurogenesis in the hippocampus suggests a
mechanism through which BDNF might be related to
depression [12].
The hippocampi of patients who suﬀer from depression
are signiﬁcantly smaller than those of healthy individuals
[13]. This may be due to the decreased neurogenesis in
depressed individuals, because hippocampal neurogenesis
is reduced by stress [12] and increased by antidepressant
treatment[14].TheparallelchangesinBDNFlevelsandneu-
rogenesis in response to stress and antidepressant treatment
suggest a positive correlation between the BDNF level and
hippocampal neurogenesis. These lines of evidence have led
totheneurotrophichypothesisofdepression[15],suggesting
that HDEA and RJ, a source of it, might inﬂuence ultimately
vulnerability to depression. HDEA and RJ are safe natural2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Chemical structure of HDEA.
products, and the latter is widely known and popular as a
health food throughout the world. Thus they might be useful
t op r o t e c ta g a i n s td e p r e s s i o n .
Therefore,wetestedtheprotectiveeﬀectofHDEAandRJ
on stress-induced depression or anxiety of model mice and,
as expected, found them to be eﬃcacious.
2.MaterialsandMethods
2.1. Animals. Seven-week-old male ddY mice (Japan SLC,
Hamamatsu, Japan), weighing 35–40g, were used. The mice
were housed under conditions of constant temperature (23 +
2◦C), humidity (55 + 10%), and a 12h light/12h dark cycle
with food and water available freely. All animal experiments
were performed according to the Guideline for Care and Use
of Laboratory Animals of Gifu Pharmaceutical University.
2.2. Drug Treatment. RJ (originated from Apis melifera)
and 10-hydroxy 2-decenoic acid (HDEA; Figure 1)w e r e
provided by Japan Beekeeping Co. Ltd. (Gifu, Japan). For
comparison with a popularly prescribed antidepressant, we
also used ﬂuvoxamine, purchased from Sigma Chemicals.
During stress exposure, RJ (250mg/kg/day), HDEA (100
or 500µg/kg/day), or ﬂuvoxamine (1000µg/kg/day), each
dissolved in phosphate-buﬀered saline (PBS), was injected
intraperitoneally into mice once a day for 21 days from the
onset of the stress loading. Alternatively, RJ (2.5g/kg/day)
was orally administered to the animals via a metal gastric
zonde.
2.3. Stress-Induced Depression-Like Model Mice. Stress-
induced depression-like model mice [16] were prepared
by a combination of modiﬁed forced swimming [17, 18]
and chronic mild stress (CMS) [19]. Brieﬂy, the mice were
individually placed into 5-L glass beakers (height 27cm,
diameter 18cm) ﬁlled with 4L of water (23 + 1◦C) and
kept there for 15min. After that, the mice were removed
and dried with a drier before being returned to their home
cages. Two days later, the caged mice were exposed to CMS,
whichconsistedof3diﬀerentandsequentialstresssituations:
inclining their cage by 20 degrees from the horizontal (CMS
1), keeping them on chip bedding wetted with 200ml of
water (CMS 2), and shaking the cages at 180rpm by a
rotatoryshaker(CMS3).Thesestresssituationswereapplied
for 48, 24, and 24hr, respectively, with a 24hr interval
between each situation.
2.4. Elevated Plus-Maze Test. This is a standard test of fear
and anxiety. After treatment, the animals were placed in the
center of a 4-arm maze (30 × 5cm/arm) elevated to a height
of 50cm, in which 2 arms were open and 2 were enclosed
[20]. The number of times the animal entered each of the
arms and the time spent in each arm were recorded during a
5-min test period. The procedure was conducted in a sound-
attenuated room.
2.5. Open-Field Test. The open-ﬁeld test is another test for
fear and anxiety, utilizing a square arena 96 × 96cm2 with
60cm high walls. The ﬂoor was divided into 16 squares by
parallel and intersecting white lines [21]. Four squares were
deﬁned as the center and the 12 squares along the walls, as
the periphery. Mice were placed in the center of the ﬁeld and
allowed to explore freely for 5min. The percent of time spent
in the center areas of the ﬁeld was calculated, and number of
squares crossed was counted.
2.6. Tail-Suspension Test. The tail-suspension test is a stan-
dard assay for depression because decreased motivation is a
hallmark symptom [22]. In this test, a mouse was suspended
by its tail from a hanger attached to a precision linear
load cell. Although measurements were taken for 7min,
immobility was calculated by determining the time spent
immobile during the last 6min of the test, because all mice
were uniformly active for the ﬁrst min. Immobility time was
scored by a blinded observer. Mice that climbed their tail or
fell oﬀ the hanger were excluded from analysis.
3. Results
3.1. Eﬀect of HDEA on the Stress-Induced Depression. Prior
to stress loading, mice were evaluated for immobility time
during the last 6min of the tail-suspension test; and
those with suspiciously low or high values (i.e., outliers)
were excluded from the study in order to minimize the
variability of immobility time. The remaining mice (n =
8/group) were administered vehicle, HDEA (100µg/kg),
HDEA (500µg/kg), or ﬂuvoxamine (1000µg/kg) once a
day for 21 days during the stress loading; then the tail-
suspension test was performed (Figure 2). The immobility
time of the stress-loaded animals was 2 times greater than
that of the nonstress-loaded animals in the vehicle-treated
group, indicating that the stress caused depression. A similar
result was obtained for the low-dose HDEA-treated group.
However, this signiﬁcant diﬀerence in immobility time
between stress loading and nonstress loading disappeared
in the high-dose HDEA-treated and ﬂuvoxamine-treated
groups, suggesting that the high-dose HDEA and ﬂuvoxam-
ine eﬀectively protected against depression.
3.2. Eﬀect of HDEA on the Stress-Induced Anxiety. At ﬁrst
mice were assessed for the number of times each animal
entered each of the arms and the time spent in each arm dur-
ing a 5-min test period in the elevated plus-maze test before
stressloading,andtheoutlierswereexcludedtominimizethe
variability of data among the subsequently treated groups.
The remaining mice (n = 8/group) were administered vehi-
cle, HDEA (100µg/kg), HDEA (500µg/kg), or ﬂuvoxamine
(1000µg/kg) once a day for 21 days during the stress loading.
They were then given 5min to explore the plus-shaped maze.Evidence-Based Complementary and Alternative Medicine 3
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Figure 2: Eﬀects of HDEA on depression in mice. The mice
were daily injected intraperitoneally with vehicle, HDEA (100 or
500µg/kg) or ﬂuvoxamine (1mg/kg) for 3 weeks with simultaneous
exposure to the stress described in Materials and Methods and then
subjected to the tail suspension test at 24hr after the end of the
stress. Signiﬁcance of diﬀerences from the values of mice without
stress exposure (control) was determined by performing Student’s
t-test (∗P<0.05, ∗∗∗P<0.001).
Thetimespentintheopenarmsbythestress-loadedanimals
was markedly shorter than that for the nonstress-loaded
ones in the vehicle-treated group, indicating that the stress
induced an anxiety state (Figure 3(a)). However, no such
signiﬁcant diﬀerence was found in the low- and high-dose
HDEA- and ﬂuvoxamine-treated groups. Furthermore, the
stress-loadedanimalsineitherHDEA-treatmentgroupspent
signiﬁcantly more time in the open arms compared with
those in the vehicle group (Figure 3(a)). The ﬁnding that
the frequency of entry into all arms was constant irrespective
of stress loading in all experimental groups demonstrated
that the locomotor activity was not inﬂuenced by the
stress loading (Figure 3(b)). These observations suggest that
HDEA was as eﬀective as ﬂuvoxamine to protect against the
anxiety.
Another approach to evaluate the anxiety state is the
open-ﬁeld test. Initially, outliers in the open-ﬁeld test were
excluded before stress loading to minimize the variability of
data among the subsequently treated groups. The retained
mice (n = 8/group) were administered vehicle or 100 or
500µg/kg of HDEA once a day for 21 days during the stress
loading. They were then given 5 min to explore an open
ﬁeld. The time spent in the central area by the stress-loaded
animals was signiﬁcantly shorter than that by the nonstress-
loaded ones in the vehicle-treated group, indicating that
the stress strengthened the anxiety state and resulted in a
signiﬁcant decrease in the time spent in the central area
(Figure 4(a)). However, no signiﬁcant diﬀerence was noted
between stress-loaded and nonstress-loaded animals when
thelow-orhigh-dose HDEAwasadministered (Figure 4(a)).
Locomotion time was unchanged irrespective of stress load-
ing in all experimental groups (Figure 4(b)), demonstrating
that the reduction in time spent in the central area was not
relatedtolocomotoractivity.Theseobservationssuggestthat
HDEA was eﬀective to protect against the anxiety also when
evaluated by the open-ﬁeld test.
3.3. Eﬀect of RJ on the Stress-Induced Depression. HDEA is
uniquely and abundantly present in RJ [23]. Therefore, we
examined the inﬂuence of RJ itself on the depression. The
experiment was conducted in the same manner as that with
HDEA or ﬂuvoxamine (Figure 2). A dose of 250mg/kg of RJ
given by the intraperitoneal route signiﬁcantly lowered the
immobility time, which had been increased by stress in the
vehicle group (Figure 5); however, much smaller doses of
RJ did not have any signiﬁcant eﬀect (data not shown). RJ
is a very popular health food and is generally taken orally.
Therefore, ﬁnally we evaluated the eﬀectiveness of orally
administered RJ for protection against depression. An enor-
mous large amount of RJ was needed for this purpose. The
signiﬁcant diﬀerence in immobility time between stressed
and nonstressed vehicle-treated groups disappeared when
RJ was taken orally at a dose of 2500mg/kg, although no
signiﬁcant diﬀerence between the stressed RJ-treated and
vehicle-treated groups was observed. These results suggest
that orally administered RJ was less eﬀective or much weaker
than that given by the intraperitoneal route.
4. Discussion
Several results suggest that BDNF may play a protective
role in the pathophysiology of depression [24]. Heterozy-
gous BDNF knockout mice show behavioral abnormali-
ties consistent with serotonergic dysfunction. Additional
evidence connecting BDNF and depression comes from
studies showing that infusion of recombinant BDNF into
the mouse midbrain [25]o rh i p p o c a m p u s[ 24]p r o d u c e sa n
antidepressant eﬀect in both learned helplessness and forced
swim models of depression. Furthermore, stress, a trigger for
depression, lowers hippocampal transcription of BDNF in
mice [26]. In contrast, numerous antidepressants, including
selective serotonin reuptake inhibitors, electroconvulsive
therapy, lithium, and monoamine oxidase inhibitors [26,
27], all increase BDNF transcription. This transcriptional
increase occurs after a delay similar to that seen in the onset
of clinical eﬀects of antidepressants [26].
BDNF binds to a speciﬁc Trk receptor tyrosine kinase
[28], which binding triggers signal transduction cascades
including the pathways of mitogen-activated protein kinases
(MAPK)/extracellular signal-regulated kinases (ERK)1/2
[29]. Activated ERK1/2 then passes into the nucleus to
activatetranscriptionfactorssuchascAMPresponseelement
binding protein (CREB), leading to regulation of expression
of various genes involved in neuronal diﬀerentiation, learn-
ing, and memory [30, 31]. Intracellular signaling through
ERK1/2 is important for the regulation of various cellular
functions in the central nervous system. Analysis of gene-
disrupted animals has clariﬁed that ERK1/2 activity may
govern neurogenesis to ensure proper brain development
[32]. Therefore, activation of ERK1/2 is a key event to
regulate neurogenesis.
Earlier we found that HDEA increases the generation of
neurons and decreases that of glial cells from cultured NSCs
[10]. This reciprocal response between neuronal and glial
populations suggests that HDEA aﬀects a neuronal lineage of
NSCs having the ability to generate both neuronal and glial4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of HDEA on the anxiety (a) and locomotor activity (b) in the elevated plus-maze test for mice. The mice were treated with
vehicle, HDEA, or ﬂuvoxamine as described in the legend of Figure 2 and then subjected to the elevated plus-maze test at 24hr after the
end of the stress loading. Signiﬁcance of diﬀerences from the values of mice without stress loading was determined by use of Student’s t-test
(∗P<0.05 as indicated by thebracket). Signiﬁcant diﬀerences fromthe value ofthe vehicle-treated mice with stressloading were determined
by performing one-way ANOVA with Tukey’s test (##P<0.01 as indicated by the brackets).
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Figure 4: Eﬀects of HDEA on the anxiety (a) and locomotor activity (b) in the open-ﬁeld test for mice. The mice were treated with vehicle
or HDEA as described in the legend of Figure 2 and then examined by the open-ﬁeld test at 24hr after the end of the stress. Signiﬁcance of
diﬀerences from the values of mice without stress loading was determined by using Student’s t-test (∗P<0.05 as indicated by the bracket).
cells. We previously observed that BDNF similarly aﬀects
cultured NSCs [11]. Thus, HDEA supposedly commits
neural progenitors to the fate of neuronal lineage similarly
as BDNF.
Previously we found that medium-chain fatty acids with
8–12 carbons and their esters facilitate the activation
(phosphorylation) of ERK 1/2 of cultured embryonic
cortical/hippocampal neurons [33]. In particular, trans-2-
decenoic acid ethyl ester (DAEE) has the most potent
activity. In that study we found that (1) DAEE stimulates
phosphorylation of ERK1/2 via MEK activation; (2) DAEE
activates CREB predominantly through ERK1/2 activation,
not through other pathways such as cAMP/protein kinase A;
(3) DAEE increases the expression of mRNAs of BDNF and
neurotrophin-3 and the protein content of synapse-speciﬁc
proteins such as synaptophysin, synapsin-1, and syntaxin
[33]. From these observations, HDEA was considered to
activate ERK1/2 followed by CREB phosphorylation, whichEvidence-Based Complementary and Alternative Medicine 5
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Figure 5: Eﬀects of RJ on depression in mice. The tail-suspension test was used for evaluation of depression in mice injected with RJ
intraperitoneally (a) or orally (b) once a day for 3 weeks with simultaneous exposure to the stress. Immobility values are expressed as the
mean + SE (n = 3–5). Signiﬁcance of diﬀerences from the values of the vehicle-treated mice without stress loading was determined by
performing Student’s t-test (∗P<0.05, ∗∗∗P<0.001 as indicated by the brackets). Signiﬁcance of diﬀerences from the values of the vehicle-
treated mice with stress exposure was determined by use of two-way ANOVA followed by the Bonferroni test (##P<0.01, as indicated by the
brackets).
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improve symptoms [34].
Dysfunctions of glucocorticoid receptors (GRs) have
been implicated in the pathogenesis of stress-related depres-
sion [35, 36]. Antidepressants increase hippocampal neuro-
genesis, which action is followed by decreased depression
and anxiety, via a GR-dependent mechanism involving GR
phosphorylation and activation of a speciﬁc set of genes
including BDNF gene [37]. Antidepressant-induced BDNF
protein functions importantly to increase neurogenesis to
ameliorate the symptoms of depression. However, Mout-
satsou et al. [38] found that HDEA did not alter the
glucocorticoid response element-mediated transcriptional
activity, suggesting that GR-dependent mechanisms are not
involved in the action mechanisms of HDEA. Therefore, the
action mechanisms of HDEA are diﬀerent from those of
antidepressants currently used, because the antidepressant
drugs are thought to activate the ERK1/2/CREB signaling
pathway via antidepressant-induced BDNF.
These results demonstrate that HDEA and RJ, a natural
source of it, are eﬀective in ameliorating the stress-inducible
symptoms of depression and anxiety and suggest that they
may become a promising tool as a new antidepressant.
Acknowledgment
This work was supported by a Grant of Gifu City Subsidiary
for Project Creation “Industry-academic-government Coop-
eration Project Subsidiary”.
References
[1] A. Fujii, S. Kobayashi, N. Kuboyama et al., “Augmentation of
wound healing by royal jelly (RJ) in streptozotocin-diabetic
rats,”Japanese Journal of Pharmacology, vol. 53, no. 3, pp. 331–
337, 1990.
[2] L. ˇ S v e r ,N .O r ˇ soli´ c, Z. Tadi´ c, B. Njari, I. Valpoti´ c, and I. Baˇ si´ c,
“A royal jelly as a new potential immunomodulator in rats and
mice,” Comparative Immunology, Microbiology and Infectious
Diseases, vol. 19, no. 1, pp. 31–38, 1996.
[ 3 ]H .O k a ,Y .E m o r i ,N .K o b a y a s h i ,Y .H a y a s h i ,a n dK .N o m o t o ,
“Suppression of allergic reactions by royal jelly in asso-
ciation with the restoration of macrophage function and
the improvement of Th1/Th2 cell responses,” International
Immunopharmacology, vol. 1, no. 3, pp. 521–532, 2001.
[4] Y. Taniguchi, K. Kohno, S. I. Inoue et al., “Oral administration
ofroyaljellyinhibitsthedevelopmentofatopicdermatitis-like
skin lesions in NC/Nga mice,” International Immunopharma-
cology, vol. 3, no. 9, pp. 1313–1324, 2003.
[5] N. Hattori, H. Nomoto, S. Mishima et al., “Identiﬁcation of
AMP N1-oxide in royal jelly as a component neurotrophic
toward cultured rat pheochromocytoma PC12 cells,” Bio-
science,BiotechnologyandBiochemistry,vol.70,no.4,pp.897–
906, 2006.
[6] M. Genc ¸ and A. Aslan, “Determination of trans-10-hydroxy-
2-decenoic acid content in pure royal jelly and royal jelly
products by column liquid chromatography,” Journal of Chro-
matography A, vol. 839, no. 1-2, pp. 265–268, 1999.
[7] G. F. Townsend, W. H. Brown, E. E. Felauer, and B. Hazlett,
“Studies on the in vitro antitumor activity of fatty acids. IV.
The esters of acids closely related to 10-hydroxy-2-decenoic
acids from royal jelly against transplantable mouse leukemia,”6 Evidence-Based Complementary and Alternative Medicine
Canadian Journal of Biochemistry and Physiology, vol. 39, pp.
1765–1770, 1961.
[ 8 ]S .K o y a - M i y a t a ,I .O k a m o t o ,S .U s h i o ,K .I w a k i ,M .I k e d a ,
and M. Kurimoto, “Identiﬁcation of a collagen production-
promoting factor from an extract of royal jelly and its possible
mechanism,” Bioscience, Biotechnology and Biochemistry, vol.
68, no. 4, pp. 767–773, 2004.
[9] M. S. Blum, A. F. Novak, and S. Taber, “10-hydroxy-delta 2-
decenoic acid, an antibiotic found in royal jelly,” Science, vol.
130, no. 3373, pp. 452–453, 1959.
[10] N. Hattori, H. Nomoto, H. Fukumitsu, S. Mishima, and
S. Furukawa, “Royal jelly and its unique fatty acid, 10-
hydroxy-trans-2-decenoicacid,promoteneurogenesisbyneu-
ralstem/progenitorcellsinvitro,” BiomedicalResearch,vol.28,
no. 5, pp. 261–266, 2007.
[11] H. Ito, A. Nakajima, H. Nomoto, and S. Furukawa, “Neu-
rotrophins facilitate neuronal diﬀerentiation of cultured neu-
ralstemcellsviainductionofmRNAexpressionofbasichelix-
loop-helix transcription factors Mash1 and Math1,” Journal of
Neuroscience Research, vol. 71, no. 5, pp. 648–658, 2003.
[12] E. Gould, A. J. Reeves, M. S. A. Graziano, and C. G. Gross,
“Neurogenesis in the neocortex of adult primates,” Science,
vol. 286, no. 5439, pp. 548–552, 1999.
[13] Y. I. Sheline, “3D MRI studies of neuroanatomic changes in
unipolar major depression: the role of stress and medical
comorbidity,” Biological Psychiatry, vol. 48, no. 8, pp. 791–800,
2000.
[14] J. E. Malberg, A. J. Eisch, E. J. Nestler, and R. S. Duman,
“Chronic antidepressant treatment increases neurogenesis in
adult rat hippocampus,” Journal of Neuroscience, vol. 20, no.
24, pp. 9104–9110, 2000.
[15] R. S. Duman, G. R. Heninger, and E. J. Nestler, “A molecular
and cellular theory of depression,” Archives of General Psychia-
try, vol. 54, no. 7, pp. 597–606, 1997.
[16] N. Ito, T. Nagai, T. Yabe, S. Nunome, T. Hanawa, and H.
Yamada, “Antidepressant-like activity of a Kampo (Japanese
herbal) medicine, Koso-san (Xiang-Su-San), and its mode
of action via the hypothalamic-pituitary-adrenal axis,” Phy-
tomedicine, vol. 13, no. 9-10, pp. 658–667, 2006.
[17] M. J. Detke, J. Johnson, and I. Lucki, “Acute and chronic
antidepressant drug treatment in the rat forced swimming test
model of depression,” Experimental and Clinical Psychophar-
macology, vol. 5, no. 2, pp. 107–112, 1997.
[18] R. D. Porsolt, A. Bertin, and M. Jalfre, “Behavioral despair in
mice: a primary screening test for antidepressants,” Archives
Internationales de Pharmacodynamie et de Th´ erapie, vol. 229,
no. 2, pp. 327–336, 1977.
[19] P. Willner, A. Towell, D. Sampson, S. Sophokleous, and
R. Muscat, “Reduction of sucrose preference by chronic
unpredictable mild stress, and its restoration by a tricyclic
antidepressant,” Psychopharmacology, vol. 93, no. 3, pp. 358–
364, 1987.
[ 2 0 ]A .L .V a l e ,S .G r e e n ,A .M .J .M o n t g o m e r y ,a n dS .S h a ﬁ ,“ T h e
nitricoxidesynthesisinhibitorL-NAMEproducesanxiogenic-
like eﬀects in the rat elevated plus-maze test, but not in the
social interaction test,” Journal of Psychopharmacology, vol. 12,
no. 3, pp. 268–272, 1998.
[21] S. K. Bhattacharya, K. S. Satyan, and A. Chakrabarti, “Anxio-
genicactionofcaﬀeine: anexperimentalstudyinrats,” Journal
of Psychopharmacology, vol. 11, no. 3, pp. 219–224, 1997.
[22] V.M.Gadotti,S.P.Bonﬁeld,andG.W.Zamponi,“Depressive-
like behavior of mice lacking cellular prion protein,” Behav-
ioral Brain Research. In press.
[23] T. Takenaka, “Chemical composition of royal jelly,” Honeybee
Science, vol. 3, pp. 69–74, 1982.
[24] R. S. Duman, “Synaptic plasticity and mood disorders,”
Molecular Psychiatry, vol. 7, supplement 1, pp. S29–S34, 2002.
[25] J. A. Siuciak, D. R. Lewis, S. J. Wiegand, and R. M. Lindsay,
“Antidepressant-like eﬀect of brain-derived neurotrophic fac-
tor (BDNF),” Pharmacology Biochemistry and Behavior, vol.
56, no. 1, pp. 131–137, 1996.
[26] M. Nibuya, S. Morinobu, and R. S. Duman, “Regulation of
BDNF and trkB mRNA in rat brain by chronic electrocon-
vulsive seizure and antidepressant drug treatments,” Journal of
Neuroscience, vol. 15, no. 11, pp. 7539–7547, 1995.
[27] A. Russo-Neustadt, R. C. Beard, and C. W. Cotman, “Exercise,
antidepressant medications, and enhanced brain derived neu-
rotrophic factor expression,” Neuropsychopharmacology, vol.
21, no. 5, pp. 679–682, 1999.
[28] M.Barbacid,“StructuralandfunctionalpropertiesoftheTRK
family of neurotrophin receptors,” Annals of the New York
Academy of Sciences, vol. 766, pp. 442–458, 1995.
[29] D. R. Kaplan and F. D. Miller, “Neurotrophin signal transduc-
tion in the nervous system,” Current Opinion in Neurobiology,
vol. 10, no. 3, pp. 381–391, 2000.
[30] E. J. Huang and L. F. Reichardt, “Neurotrophins: roles
in neuronal development and function,” Annual Review of
Neuroscience, vol. 24, pp. 677–736, 2001.
[31] Q. Lu, A. E. Hutchins, C. M. Doyle, J. R. Lundblad, and R.
P. S. Kwok, “Acetylation of cAMP-responsive element-binding
protein (CREB) by CREB-binding protein enhances CREB-
dependent transcription,” Journal of Biological Chemistry, vol.
278, no. 18, pp. 15727–15734, 2003.
[32] Y. Satoh, Y. Kobayashi, A. Takeuchi, G. Pag` es, J. Pouyss´ egur,
and T. Kazama, “Deletion of ERK1 and ERK2 in the CNS
causes cortical abnormalities and neonatal lethality: Erk1
deﬁciency enhances the impairment of neurogenesis in Erk2-
deﬁcient mice,” Journal of Neuroscience,v o l .3 1 ,n o .3 ,p p .
1149–1155, 2011.
[33] A. Makino, M. Iinuma, H. Fukumitsu, H. Soumiya, Y.
Furukawa, and S. Furukawa, “2-decenoic acid ethyl ester
possesses neurotrophin-like activities to facilitate intracellular
signals and increase synapse-speciﬁc proteins in neurons
cultured from embryonic rat brain,” Biomedical Research, vol.
31, no. 6, pp. 379–386, 2010.
[34] S. E. Hyman and E. J. Nestler, “Initiation and adaptation:
a paradigm for understanding psychotropic drug action,”
American Journal of Psychiatry, vol. 153, no. 2, pp. 151–162,
1996.
[35] F. Holsboer, “The corticosteroid receptor hypothesis of
depression,”Neuropsychopharmacology,vol.23,no.5,pp.477–
501, 2000.
[ 3 6 ]E .J .N e s t l e r ,M .B a r r o t ,R .J .D i L e o n e ,A .J .E i s c h ,S .J .G o l d ,
and L. M. Monteggia, “Neurobiology of depression,” Neuron,
vol. 34, no. 1, pp. 13–25, 2002.
[37] C.Anacker,P.A.Zunszain,A.Cattaneoetal.,“Antidepressants
increase human hippocampal neurogenesis by activating the
glucocorticoid receptor,” Molecular Psychiatry,v o l .1 6 ,n o .7 ,
pp. 738–750, 2011.
[38] P. Moutsatsou, Z. Papoutsi, E. Kassi et al., “Fatty acids
derived from royal jelly are modulators of estrogen receptor
functions,” PLoS One, vol. 5, no. 12, Article ID e15594, 2010.